Clinical Scorecard: Analysis of Clinical Outcomes from Medicinal Cannabis Treatment for Fibromyalgia: Insights from the UK Medical Cannabis Registry
At a Glance
Category
Detail
Condition
Fibromyalgia characterized by generalized pain lasting ≥3 months with tender points and somatic symptoms
Key Mechanisms
Nociplastic pain via central nervous system sensitization; CBMPs act on CB1R and CB2R receptors with analgesic, sleep-promoting, and anxiolytic effects
Target Population
Adults diagnosed with fibromyalgia refractory to licensed therapies
Care Setting
Specialist clinics prescribing cannabis-based medicinal products within the UK Medical Cannabis Registry
Key Highlights
Fibromyalgia affects ~5.4% of adults, predominantly females, with significant impact on quality of life and work capacity
Current first-line pharmacotherapies have small effect sizes and high discontinuation rates due to adverse events
CBMPs, containing THC and CBD, show potential for symptom relief but evidence is limited by small RCTs and heterogeneity
Guideline-Based Recommendations
Diagnosis
Diagnosis confirmed by consultant physician based on clinical criteria including pain duration and symptomatology
Management
First-line treatments include pregabalin and antidepressants (duloxetine, amitriptyline, milnacipran)
CBMPs may be considered as adjunctive therapy when standard care is insufficient, especially with impaired sleep
CBMPs prescribed only after failure of licensed therapies, formulations include oils, capsules, pastilles, lozenges, and inhaled dried flower
Monitoring & Follow-up
Patient-reported outcome measures (PROMs) collected at baseline and follow-ups (1, 3, 6, 12, 18 months)
Adverse events monitored and reported regularly
Risks
Adverse events are mostly mild to moderate
High rates of medication discontinuation with standard therapies due to tolerability issues
Patient & Prescribing Data
Patients with fibromyalgia enrolled in the UK Medical Cannabis Registry who failed licensed therapies
CBMPs associated with improvements in fibromyalgia-specific and general health PROMs over 12 months; inhalation is a common administration route despite limited RCT data
Clinical Best Practices
Confirm fibromyalgia diagnosis by specialist prior to CBMP initiation
Reserve CBMPs for patients refractory to licensed pharmacotherapies
Use multiple PROMs and regular follow-up intervals to assess efficacy and safety
Counsel patients against non-prescribed cannabis use at baseline
Consider patient history including comorbidities, substance use, and baseline characteristics for individualized treatment
by Madhur Varadpande, Simon Erridge, Arushika Aggarwal, Evonne Clarke, Katy McLachlan, Ross Coomber, Shelley Barnes, Alia Darweish Medniuk, Rahul Guru, Wendy Holden, Mohammed Sajad, Robert Searle, Azfer Usmani, Sanjay Varma, James J. Rucker, Michael Platt, Mikael H. Sodergren
